Ozempic
Page 2 of 9
CommentaryThe crisis over GLP-1 out-of-pocket costs deepens—it’s time for health-care leaders to step up
By Wendy BarnesMarch 4, 2025
Health50-year-old security guard lost 70 pounds on Wegovy—then gained two pants sizes when he lost insurance coverage
By Tom Murphy and The Associated PressFebruary 24, 2025
By Bloomberg, Madison Muller, Ike Swetlitz and Naomi KresgeFebruary 21, 2025
By Lindsey LeakeFebruary 11, 2025
LeadershipAs U.S. firms scrap diversity targets, the CEO behind Ozempic and Wegovy took a pay cut for missing them
By Ryan HoggFebruary 5, 2025
HealthAs growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs
By Ryan HoggFebruary 5, 2025
HealthHims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs
By Lindsey LeakeFebruary 3, 2025
HealthOzempic and Wegovy surge to national approval with most U.S. adults considering it ‘a good thing’ to treat obesity
By The Associated Press, Kenya Hunter and Linley SandersJanuary 31, 2025
By Aaron Clark and BloombergJanuary 31, 2025
HealthOnline searches predicted the surge in prescriptions of weight-loss drugs like Wegovy and Zepbound, study says. Here’s what could happen next
By Lindsey LeakeJanuary 29, 2025
By Greg McKennaJanuary 24, 2025
By Lindsey LeakeJanuary 21, 2025
HealthLargest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease
By Carolyn BarberJanuary 20, 2025
By Ani FreedmanJanuary 14, 2025
Most Popular
